US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Neo-Concept International Group Holdings Limited

0.4200

+0.02105.26%

Volume:60.32K

Turnover:23.88K

Market Cap:8.53M

PE:5.50

High:0.4399

Open:0.4000

Low:0.3769

Close:0.3990

Loading ...

Overview Company News Filings

Neo-Concept International Group H1 2024 EPS $0.01; Revenue $10.15M

Neo-Concept International Group Holdings Limited Announces First Half 2024 Unaudited Financial Results

THOMSON REUTERS

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial

Press Release: Shell plc Third Quarter 2024 Euro and GBP Equivalent Dividend Payments

BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Press Release: Shell completes sale of Sinco pipeline system and Colex terminal to Edgewater Midstream

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

Aptose and NCI Collaborate on Cancer Drug Trials

BRIEF-Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials

Aptose Biosciences signs CRADA with NCI to develop tuspetinib for AML, MDS

Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference

Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases

AECOM reports fourth quarter and full year fiscal 2024 results

Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024

Valero Energy Corp (NYSE:VLO): A Bullish Investment Perspective

Press Release: SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Press Release: QT Imaging Announces Third Quarter 2024 Financial Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NCI/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NCI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","market":"US","secType":"STK","nameCN":"Neo-Concept International Group Holdings Limited","latestPrice":0.42,"timestamp":1745438400000,"preClose":0.399,"halted":0,"volume":60324,"delay":0,"floatShares":1726200,"shares":20320000,"eps":0.076408,"marketStatus":"Post-Mkt","change":0.021,"latestTime":"04-23 17:32:33 EDT","open":0.4,"high":0.4399,"low":0.3769,"amount":23879.669371,"amplitude":0.157895,"askPrice":0.4342,"askSize":100,"bidPrice":0.38,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":0.076408,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745452800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1713844800000,"exchange":"NASDAQ","adjPreClose":0.399,"dividendRate":0.47619,"volumeRatio":1.219963},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","floatShares":1726200,"roa":"6.28%","roe":"58.31%","lyrEps":0.031396,"volumeRatio":1.219963,"shares":20320000,"dividePrice":0.2,"high":0.4399,"amplitude":0.157895,"preClose":0.399,"low":0.3769,"week52Low":0.3501,"pbRate":"1.33","psRate":"0.38","week52High":11.39,"institutionHeld":0.7857,"latestPrice":0.42,"committee":0.818182,"eps":0.076408,"divideRate":0.47619,"volume":60324,"delay":0,"ttmEps":0.076408,"open":0.4,"prevYearClose":0.66,"prevWeekClose":0.4399,"prevMonthClose":0.48,"prevQuarterClose":0.48,"fiveDayClose":0.4274,"twentyDayClose":0.45,"sixtyDayClose":0.69},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NCI\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2492317646","title":"Neo-Concept International Group H1 2024 EPS $0.01; Revenue $10.15M","url":"https://stock-news.laohu8.com/highlight/detail?id=2492317646","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492317646?lang=en_us&edition=fundamental","pubTime":"2024-12-19 22:19","pubTimestamp":1734617953,"startTime":"0","endTime":"0","summary":"Neo-Concept International Group H1 2024 EPS $0.01; Revenue $10.15M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/12/42589105/neo-concept-international-group-h1-2024-eps-0-01-revenue-10-15m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Neo-Concept International Group H1 2024 EPS $0.01; Revenue $10.15M","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI"],"gpt_icon":0},{"id":"2492175157","title":"Neo-Concept International Group Holdings Limited Announces First Half 2024 Unaudited Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2492175157","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492175157?lang=en_us&edition=fundamental","pubTime":"2024-12-19 22:00","pubTimestamp":1734616809,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUA7SDCJH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NCI","BK4202"],"gpt_icon":0},{"id":"2492959911","title":"Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2492959911","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492959911?lang=en_us&edition=fundamental","pubTime":"2024-12-17 20:30","pubTimestamp":1734438600,"startTime":"0","endTime":"0","summary":"Single intrathecal dose of Rhenium (186Re) Obisbemeda delivers favorable responses in cerebrospinal fluid circulating tumor cell count, imaging, and clinical evaluation Both single-dose and multiple-d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/17/2998156/0/en/Plus-Therapeutics-Presents-Positive-ReSPECT-LM-Phase-1-Interim-Data-for-Breast-Cancer-Patients-with-Leptomeningeal-Metastases-at-the-2024-San-Antonio-Breast-Cancer-Symposium.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSF","LENZ","BK4139","BK4202","NCI"],"gpt_icon":0},{"id":"2490866155","title":"LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2490866155","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490866155?lang=en_us&edition=fundamental","pubTime":"2024-12-11 23:15","pubTimestamp":1733930100,"startTime":"0","endTime":"0","summary":"First and only PARP inhibitor to improve survival in early breast cancer. WILMINGTON, Del., December 11, 2024----Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc’s, known as MSD outside of the US and Canada, LYNPARZA  demonstrated sustained, clinically meaningful improvements in overall survival , invasive disease-free survival  and distant disease-free survival  at six years for patients with germline BRCA-mutated  HER2-negative high-risk early breast cancer.Eliav Barr, Senior Vice President, Head of Global Clinical Development and C","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ARG9pBkQU.InVGzB47YqBg--~B/aD00NzU7dz0xNDM4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8ec7ccdd0c2fab1da78e61eea7bf33a6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ARG9pBkQU.InVGzB47YqBg--~B/aD00NzU7dz0xNDM4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8ec7ccdd0c2fab1da78e61eea7bf33a6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lynparza-olaparib-demonstrated-clinically-meaningful-151500770.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HR","LU1829250122.USD","III","LU0320765992.SGD","LU2106854487.HKD","LU1974910355.USD","BK4203","OS","LU2417539215.USD","BK4134","BK4516","BK4568","LU0109394709.USD","BK4007","LU2456880835.USD","BK4104","BIG","LU2023250843.SGD","AZN","LU1917777945.USD","BK4097","BK4202","BK4225","BK4220","BK4588","LU0889565916.HKD","BK4114","NCI","LU2462157665.USD","BK4585","LU2236285917.USD","LU2023250504.SGD","URI","LU1721428933.USD"],"gpt_icon":0},{"id":"2490071966","title":"Press Release: Shell plc Third Quarter 2024 Euro and GBP Equivalent Dividend Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2490071966","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490071966?lang=en_us&edition=fundamental","pubTime":"2024-12-09 15:00","pubTimestamp":1733727600,"startTime":"0","endTime":"0","summary":"SHELL PLC THIRD QUARTER 2024 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS. The Board of Shell plc today announced the pounds sterling and euro equivalent dividend payments in respect of the third quarter 2024 interim dividend, which was announced on October 31, 2024 at US$0.344 per ordinary share.Shareholders have been able to elect to receive their dividends in US dollars, euros or pounds sterling. Holders of ordinary shares who have validly submitted US dollars, euros or pounds sterling currency elections by November 29, 2024 will be entitled to a dividend of US$0.344, EUR0.3262 or 27.03p per ordinary share, respectively.Absent any valid election to the contrary, persons holding their ordinary shares through Euroclear Nederland will receive their dividends in euros at the euro rate per ordinary share shown above. Absent any valid election to the contrary, shareholders  and persons holding their shares through the Shell Corporate Nominee will receive their dividends in pounds sterling, a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0300736062.USD","BK4201","LU1162221912.USD","BK4585","LU0098860793.USD","BK4202","LU0300736492.USD","LU0320765646.SGD","LU2236285917.USD","SHEL","LU0278409577.USD","BK4588","NCI"],"gpt_icon":0},{"id":"2489222687","title":"BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2489222687","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489222687?lang=en_us&edition=fundamental","pubTime":"2024-12-07 23:00","pubTimestamp":1733583600,"startTime":"0","endTime":"0","summary":"Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96%. THOUSAND OAKS, Calif., Dec. 7, 2024 /PRNewswire/ -- Amgen  today announcednew data demonstrating that adding BLINCYTO  to chemotherapy significantly improves disease-free survival  in newly diagnosed pediatric patients with National Cancer Institute  standard risk  B-cell acute lymphoblastic leukemia  of average or higher risk of relapse. The data are from a Phase 3 study  conducted by the Children's Oncology Group. The results were simultaneously publishedin the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8, at 2 p.m. PT at the 66th American Society of Hematology  Annual Meeting & Exposition in San Diego.The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved i","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fXOCbBYEhALvuJbXuwlWEQ--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fXOCbBYEhALvuJbXuwlWEQ--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/blincyto-blinatumomab-added-chemotherapy-significantly-150000076.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/blincyto-blinatumomab-added-chemotherapy-significantly-150000076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALT","BK4135","NCI","LU0106831901.USD","LU2360107671.USD","BK4196","MAS","LU1620156130.USD","BK4097","BK4166","CI","LU2125910500.SGD","IE00B7SZL793.SGD","BK4533","LU1861220207.SGD","IE0031619046.USD","IE00B2B36J28.USD","BK4139","AST","LU1059921491.USD","TLS","HR","IE0002141913.USD","IE00B19Z3B42.SGD","IE00B19Z4B17.USD","LU1165135440.EUR","ASH","CNS","AMGN","IE00BFTCPJ56.SGD","LU0985320562.USD","CELL","LU1596574779.USD","SR","LU1023059063.AUD","BK4006","IE00B19Z3581.USD","DFS","LU1861217088.USD","LU0122379950.USD","LU1571399168.USD","IE00BJJMRZ35.SGD","ALL","BK4588","BK4156","CRS","LU1261432733.SGD","CLS","LU0170899867.USD"],"gpt_icon":0},{"id":"2488595160","title":"Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2488595160","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488595160?lang=en_us&edition=fundamental","pubTime":"2024-12-04 20:30","pubTimestamp":1733315400,"startTime":"0","endTime":"0","summary":"Company to present ReSPECT-LM Phase 1 trial data on Rhenium (186Re) Obisbemeda with a focus on treating leptomeningeal metastases (LM) in breast cancer patients AUSTIN, Texas, Dec.  04, 2024  (GLOBE N","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/04/2991382/0/en/Plus-Therapeutics-to-Showcase-ReSPECT-LM-Phase-1-Interim-Data-for-Leptomeningeal-Metastases-at-the-2024-San-Antonio-Breast-Cancer-Symposium.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSF","CNS","LENZ","BK4139","NCI","BK4202","BK4135"],"gpt_icon":0},{"id":"2488694991","title":"Press Release: Shell completes sale of Sinco pipeline system and Colex terminal to Edgewater Midstream","url":"https://stock-news.laohu8.com/highlight/detail?id=2488694991","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488694991?lang=en_us&edition=fundamental","pubTime":"2024-12-03 23:01","pubTimestamp":1733238060,"startTime":"0","endTime":"0","summary":"HOUSTON, Dec. 3, 2024 /PRNewswire/ -- Shell Pipeline Company LP and. Triton West LLC, subsidiaries of Shell USA, Inc. , have completed. the previously announced 100% sale of the Sinco pipeline system and. Colex terminal to a subsidiary of Edgewater Midstream LLC .This sale simplifies Shell's portfolio, enabling redeployment of capital. Following the sale of Shell's equity share in the Deer Park Refinery in. 2022, these assets were non-integrated and no longer fit within Shell's. -- The Sinco pipeline system and the Colex terminal are located in the. Houston Ship Channel area and have historically been operated as. -- In 2022, Shell completed the sale of its equity share in the Deer Park. Refinery to Pemex, rendering the Sinco pipeline and the Colex terminal. -- Both Shell Pipeline Company LP and Triton West LLC are subsidiaries of. pipelines and terminals in proximity to major North American petroleum. annually through its vast network of pipelines and tank farms, ensuring. Shell's U.S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4201","LU0300736062.USD","BK4588","LU0300736492.USD","LU2236285917.USD","LU0278409577.USD","LU0320765646.SGD","SHEL","NCI","BK4585","LU1162221912.USD","LU0098860793.USD","BK4202"],"gpt_icon":0},{"id":"2488910690","title":"Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2488910690","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488910690?lang=en_us&edition=fundamental","pubTime":"2024-12-03 21:30","pubTimestamp":1733232600,"startTime":"0","endTime":"0","summary":"ENV105 can potentially address resistance in a wide range of cancers as they become resistant to standard treatments.LOS ANGELES, December 03, 2024----Kairos Pharma Ltd. , a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, today announces the addition of City of Hope Cancer Center in Duarte, California to the Phase 2 clinical trial for ENV105 for castrate-resistant prostate cancer patients.City of Hope Cancer Center is the first of several planned new centers to be added in the coming weeks to support the Company’s randomized trial for patients receiving either apalutamide or apalutamide+ENV105 combination therapy. The additional centers allow Kairos Pharma to test ENV105 in a broader patient population to identify blood markers that could help select patients expected to benefit most from ENV105 treatment. The trial is supported by Kairos Pharma Ltd. and a grant from the National Cancer Institute .This pre","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ijWwXjgPhNVNW.SLpaS2oQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a58eb5cf675810d6dd8fe6b86f3e5cc6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ijWwXjgPhNVNW.SLpaS2oQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a58eb5cf675810d6dd8fe6b86f3e5cc6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kairos-pharma-adds-city-hope-133000317.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CHCO","KAPA","NCI","HOPE","KAIR","BK4139","BK4202","BK4211"],"gpt_icon":0},{"id":"2488728912","title":"Aptose and NCI Collaborate on Cancer Drug Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2488728912","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488728912?lang=en_us&edition=fundamental","pubTime":"2024-12-03 21:09","pubTimestamp":1733231387,"startTime":"0","endTime":"0","summary":"Aptose Biosciences (TSE:APS) has released an update. Aptose Biosciences has partnered with the National Cancer Institute to develop tuspetinib for ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aptose-and-nci-collaborate-on-cancer-drug-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aptose-and-nci-collaborate-on-cancer-drug-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4202","NCI"],"gpt_icon":0},{"id":"2488115519","title":"BRIEF-Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2488115519","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488115519?lang=en_us&edition=fundamental","pubTime":"2024-12-03 20:40","pubTimestamp":1733229604,"startTime":"0","endTime":"0","summary":"Dec 3 (Reuters) - Aptose Biosciences Inc   :   * APTOSE SIGNS CRADA WITH NCI TO DEVELOP TUSPETINIB FOR AML AND MDS IN NEWLY LAUNCHED MYELOMATCH PRECISION MEDICINE TRIALSSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI","BK4202"],"gpt_icon":0},{"id":"2488911548","title":"Aptose Biosciences signs CRADA with NCI to develop tuspetinib for AML, MDS","url":"https://stock-news.laohu8.com/highlight/detail?id=2488911548","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488911548?lang=en_us&edition=fundamental","pubTime":"2024-12-03 20:35","pubTimestamp":1733229308,"startTime":"0","endTime":"0","summary":"Aptose Biosciences (APTO) announced that the National Cancer Institute, NCI, part of the National Institutes of Health, and Aptose Biosciences Inc....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aptose-biosciences-signs-crada-with-nci-to-develop-tuspetinib-for-aml-mds?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aptose-biosciences-signs-crada-with-nci-to-develop-tuspetinib-for-aml-mds?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NCI","APTO","BK4202"],"gpt_icon":0},{"id":"2488553911","title":"Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply","url":"https://stock-news.laohu8.com/highlight/detail?id=2488553911","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488553911?lang=en_us&edition=fundamental","pubTime":"2024-12-03 20:30","pubTimestamp":1733229000,"startTime":"0","endTime":"0","summary":"Five-year renewable agreement secures reliable cGMP rhenium-186 (Re-186) supply for late-stage clinical and commercial forecastsAUSTIN, Texas, Dec.  03, 2024  (GLOBE NEWSWIRE) -- Plus Therapeutics, In","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/03/2990474/0/en/Plus-Therapeutics-Expands-Strategic-Agreement-with-Telix-IsoTherapeutics-Group-for-Rhenium-186-Radioisotope-Supply.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1815336091.USD","LU2125909759.SGD","LU2125909916.SGD","LU0757428866.USD","LENZ","LU0053671581.USD","BK4202","LU1923622291.USD","BK4143","NCI","LU0728928796.USD","MSA","BK4139"],"gpt_icon":0},{"id":"2486855110","title":"Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2486855110","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486855110?lang=en_us&edition=fundamental","pubTime":"2024-11-25 20:30","pubTimestamp":1732537800,"startTime":"0","endTime":"0","summary":"Single intrathecal dose of Rhenium (186Re) Obisbemeda shows a favorable response rate and median overall survival in leptomeningeal metastases (LM) patients Achieves up to 8x absorbed radiation dose t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/25/2986577/0/en/Plus-Therapeutics-Presents-Positive-ReSPECT-LM-Phase-1-Interim-Data-for-Leptomeningeal-Metastases-at-the-2024-SNO-Annual-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","CSF","BK4139","NCI","BK4202"],"gpt_icon":0},{"id":"2485498812","title":"Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2485498812","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485498812?lang=en_us&edition=fundamental","pubTime":"2024-11-21 20:30","pubTimestamp":1732192200,"startTime":"0","endTime":"0","summary":"CNSide Cerebrospinal Fluid (CSF) Assay analyzed 258 CSF samples across 66 leptomeningeal metastases (LM) patients at five institutions CNSide identified extensive, actionable mutational changes, and c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/21/2985113/0/en/Plus-Therapeutics-to-Present-Multi-Institutional-Experience-Using-the-CNSide-Cerebrospinal-Fluid-Assay-in-Patients-with-Leptomeningeal-Metastases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGS","BK4202","NCI","CSF","BK4179","LENZ"],"gpt_icon":0},{"id":"2484981895","title":"AECOM reports fourth quarter and full year fiscal 2024 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2484981895","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484981895?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:05","pubTimestamp":1731963900,"startTime":"0","endTime":"0","summary":"Fiscal 2025 guidance includes record net service revenue, margins and earnings. Increased the share repurchase authorization to $1 billion and the quarterly dividend by 18%. DALLAS, November 18, 2024----AECOM , the trusted global infrastructure leader, today reported fourth quarter and full year fiscal 2024 results.Fourth Quarter and Full Year Fiscal 2024 Highlights:. Fourth quarter adjusted1 EBITDA4 and adjusted1 EPS increased by 15% and 26%, respectively.For the full year, adjusted1 EBTDA4 and adjusted1 EPS increased 14% and 22%, respectively.The adjusted EBITDA margin5 was 16.7% in the fourth quarter and 16.0% for the full year, reflecting an increase of 140 basis points and 100 basis points, respectively.The segment adjusted1 operating margin3 was 16.7% in the fourth quarter; for the full year, the margin was 15.8%, which exceeded guidance of 15.6%.Design book-to-burn8 in the fourth quarter was 1.2x, including 1.2x in both the Americas and International s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aecom-reports-fourth-quarter-full-210500752.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4129","LU2308191902.HKD","NSR","BK4202","NCI","BK4516","ACM"],"gpt_icon":0},{"id":"2484622807","title":"Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2484622807","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484622807?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:00","pubTimestamp":1731934800,"startTime":"0","endTime":"0","summary":"- Actimab-A selected for National Cancer Institute's recently opened myeloMATCH precision medicines program for patients with acute myeloid leukemia and myelodysplastic syndromes. - Two Iomab-ACT INDs cleared by FDA: Commercial CAR-T trial at University of Texas Southwestern and sickle cell transplant trial at Columbia University; proof-of-concept safety and efficacy data expected in 2025. - Actinium seeking U.S. strategic partner for Iomab-B to conduct dose optimization and head-to-head Phase 3 trial based on FDA guidance in adult patients with active relapsed or refractory acute myeloid leukemia. - Accomplished biopharma industry executive June Almenoff, M.D., Ph.D., appointed to Actinium's Board of Directors. - Cash and cash equivalents of approximately $78.6 million as of September 30, 2024, is expected to fund operations into 2027. Sandesh Seth, Actinium's Chairman and CEO, stated, \"During the third quarter and over the last several weeks, we have made significant progress with ou","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/57avoh2.1orfF.ef8KKSbQ--~B/aD05Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/eb2937f11974a18d93e636c38ac22747","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/57avoh2.1orfF.ef8KKSbQ--~B/aD05Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/eb2937f11974a18d93e636c38ac22747"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-highlights-antibody-radiation-130000950.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-highlights-antibody-radiation-130000950.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACT","ATNM","NCI","BK4202","BK4195","BK4229","BK4139"],"gpt_icon":0},{"id":"2483124725","title":"Valero Energy Corp (NYSE:VLO): A Bullish Investment Perspective","url":"https://stock-news.laohu8.com/highlight/detail?id=2483124725","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483124725?lang=en_us&edition=fundamental","pubTime":"2024-11-16 22:56","pubTimestamp":1731769000,"startTime":"0","endTime":"0","summary":"We came across abullish thesis onValero Energy Corp  on ValueInvestorsClub by Alejo Velez. In this article, we will summarize the bulls’ thesis on VLO. VLO’s stock was trading at $151 when this thesis was published, vs. a closing price of $137.02 on November 12.VLO is one of the dominant leaders in the global refining industry which comprises complex refineries in the United States and the United Kingdom. With time, VLO has posted high returns despite the volatility of the oil industry. The company has been compounding at 15.5% annually since its IPO in 1997 and its dividend has grown by 15%, helping shareholders even through downturns.Recently, the energy sector’s transition to electric vehicles  threatens to reduce oil demand, with an expected decrease of 30-50% by 2050. Although this has its demerits, VLO has been able to adapt by taking advantage of the growing scarcity of refining capacity around the world.READ NEXT:8 Best Wide Moat Stocks to Buy Nowand30 Most Important AI Stocks ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/EzVuSeww9h7W33JqaIs50w--~B/aD02MzA7dz05NzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/30d4f1a00a7ea790808c59580d3a24cb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/EzVuSeww9h7W33JqaIs50w--~B/aD02MzA7dz05NzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/30d4f1a00a7ea790808c59580d3a24cb"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/valero-energy-corp-nyse-vlo-145640797.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B3CCJ963.GBP","SG9999001440.SGD","BK4202","VLO","IE00BGHQF524.EUR","IE00B2Q91V27.USD","LU0345781412.USD","LU0368265418.SGD","LU0345780950.USD","NYSE","LU0456854461.SGD","LU0266512127.USD","LU0122376428.USD","LU0788109394.HKD","IE00BSNM7G36.USD","NCI","BK4138","LU0300736492.USD","LU0630314457.HKD","BK4585","BK4588"],"gpt_icon":0},{"id":"2483868077","title":"Press Release: SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483868077","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483868077?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:15","pubTimestamp":1731532500,"startTime":"0","endTime":"0","summary":"-- Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia  Remains on Track for Q4 2024 --. -- GPS Granted FDA Rare Pediatric Disease Designation  for the Treatment of Pediatric AML --. NEW YORK, Nov. 13, 2024  -- SELLAS Life Sciences Group, Inc.  , a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update.Phase 3 REGAL study in AML: In June, the IDMC conducted a prespecified risk-benefit assessment of unblinded data from the study and recommended that the trial continue without modifications. Based on a detailed analysis of all unblinded data, the IDMC projected that the interim analysis  will occur in the fourth quarter of 2024.Granted FDA Rare Pediatric Disease Designation : The FDA granted Rare Pediatric Disease Designation  to GPS for the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLS","LU2463526074.USD","NCI","BK4139","BK4109","ASH","BK4202"],"gpt_icon":1},{"id":"2483100044","title":"Press Release: QT Imaging Announces Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483100044","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483100044?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:32","pubTimestamp":1731504720,"startTime":"0","endTime":"0","summary":"Generated Scanner Sales Revenue of $0.9 Million with 65% Gross Margin in the Third Quarter of 2024. The Company Successfully Completed the Engineering and Clinical Feasibility Study with its Strategic Partner. The Company Announced Entering into Favorable Amendments to Its $10 Million Convertible Promissory Note with YA II PN, Ltd.\"During this quarter, QT Imaging's team successfully completed the engineering and clinical feasibility study with our strategic partner and shipped two QT Breast Acoustic CT Scanners to a nationally recognized clinical site and to a functional medicine clinic in Illinois, together with our distribution partner, NXC Imaging. The third-year renewal of our five-year research grant from the National Institutes of Health /National Cancer Institute  was signed during the quarter,\" said Dr. Raluca Dinu, QT Imaging Chief Executive Officer.During this quarter, QT Imaging successfully amended the convertible note with YA II PN, Ltd after making a payment of approximat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","BK4585","NCI","BK4082","03160","QTI","BK4588","BK4202","BK4555","BK4099"],"gpt_icon":1}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":108,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NCI\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NCI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NCI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NCI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NCI","date":"2025-04-22","current":5.658267,"percent":0.08658,"low":-615.963293,"twenty":6.492664,"median":16.072677,"eighty":24.474222,"high":50.080918,"avg":6.900676,"sd":53.042329,"marketCap":8026400},"quantilePoints":[{"date":"2024-04-26","current":-152.934443,"twenty":-421.533502,"median":-222.424043,"eighty":-152.416021,"marketCap":47955200},{"date":"2024-05-03","current":-75.704037,"twenty":-208.526123,"median":-121.807344,"eighty":-81.702314,"marketCap":23774400},{"date":"2024-05-10","current":-74.39805,"twenty":-152.15681,"median":-81.565326,"eighty":-71.297323,"marketCap":23368000},{"date":"2024-05-17","current":36.631419,"twenty":-133.739762,"median":-74.39805,"eighty":-23.514082,"marketCap":20726400},{"date":"2024-05-24","current":30.19238,"twenty":-105.051475,"median":-71.169081,"eighty":36.421773,"marketCap":17068800},{"date":"2024-05-31","current":28.783514,"twenty":-89.228644,"median":-65.79629,"eighty":35.854613,"marketCap":16256000},{"date":"2024-06-07","current":28.579978,"twenty":-81.702314,"median":24.992177,"eighty":34.642796,"marketCap":16154400},{"date":"2024-06-14","current":31.815689,"twenty":-79.845114,"median":25.185699,"eighty":33.392506,"marketCap":17983200},{"date":"2024-06-21","current":25.826264,"twenty":-75.704037,"median":25.951163,"eighty":31.815689,"marketCap":14610080},{"date":"2024-06-28","current":24.010495,"twenty":-75.181642,"median":25.826264,"eighty":31.166365,"marketCap":13573760},{"date":"2024-07-05","current":21.847045,"twenty":-74.134092,"median":24.992177,"eighty":30.05711,"marketCap":12350496},{"date":"2024-07-12","current":24.005484,"twenty":-72.824666,"median":24.22361,"eighty":29.406809,"marketCap":13573760},{"date":"2024-07-15","current":23.309684,"twenty":-72.571072,"median":24.010495,"eighty":29.29759,"marketCap":13183616},{"date":"2024-08-02","current":17.799213,"twenty":-72.317479,"median":24.00799,"eighty":29.18837,"marketCap":10054336},{"date":"2024-08-09","current":15.712059,"twenty":-71.040839,"median":23.456094,"eighty":28.858081,"marketCap":8900160},{"date":"2024-08-16","current":14.71315,"twenty":-69.000048,"median":23.177414,"eighty":28.661392,"marketCap":8331200},{"date":"2024-08-23","current":15.475212,"twenty":-65.359249,"median":22.360574,"eighty":28.479131,"marketCap":8761984},{"date":"2024-08-30","current":15.211668,"twenty":-16.796281,"median":21.73132,"eighty":28.375818,"marketCap":8611616},{"date":"2024-09-06","current":15.60865,"twenty":14.533412,"median":17.564477,"eighty":28.127716,"marketCap":8839200},{"date":"2024-09-13","current":18.316746,"twenty":14.714645,"median":17.091682,"eighty":27.226945,"marketCap":10363200},{"date":"2024-09-20","current":30.136472,"twenty":14.729124,"median":17.451967,"eighty":27.226945,"marketCap":17068800},{"date":"2024-09-27","current":18.155945,"twenty":14.756986,"median":17.799213,"eighty":26.316487,"marketCap":10304272},{"date":"2024-10-04","current":24.668714,"twenty":14.779837,"median":18.134605,"eighty":27.226945,"marketCap":14022832},{"date":"2024-10-11","current":19.411936,"twenty":14.800605,"median":18.316746,"eighty":26.316487,"marketCap":11029696},{"date":"2024-10-18","current":27.159393,"twenty":14.841085,"median":19.188638,"eighty":26.316487,"marketCap":15422880},{"date":"2024-10-25","current":22.801653,"twenty":14.96086,"median":20.067961,"eighty":27.538745,"marketCap":12954000},{"date":"2024-10-31","current":26.444278,"twenty":15.097424,"median":21.615595,"eighty":28.23974,"marketCap":15016480},{"date":"2024-11-08","current":25.398607,"twenty":15.188698,"median":21.880614,"eighty":27.72766,"marketCap":14427200},{"date":"2024-11-15","current":22.207911,"twenty":15.214052,"median":22.207911,"eighty":27.409251,"marketCap":12598400},{"date":"2024-11-22","current":20.742686,"twenty":15.227723,"median":22.212919,"eighty":27.092873,"marketCap":11765280},{"date":"2024-11-29","current":19.71984,"twenty":15.244259,"median":22.031838,"eighty":26.826792,"marketCap":11184128},{"date":"2024-12-06","current":19.342155,"twenty":15.419442,"median":21.847045,"eighty":26.825987,"marketCap":10972800},{"date":"2024-12-13","current":18.931587,"twenty":15.475212,"median":20.935809,"eighty":26.444278,"marketCap":10749280},{"date":"2024-12-20","current":16.81288,"twenty":15.549996,"median":20.067961,"eighty":26.379894,"marketCap":9550400},{"date":"2024-12-27","current":7.581302,"twenty":15.240125,"median":20.023482,"eighty":26.25308,"marketCap":10741152},{"date":"2025-01-03","current":8.618162,"twenty":15.140189,"median":19.71984,"eighty":26.21899,"marketCap":12196064},{"date":"2025-01-10","current":10.05795,"twenty":14.800605,"median":19.685908,"eighty":26.181452,"marketCap":14224000},{"date":"2025-01-17","current":8.786233,"twenty":14.714645,"median":19.468094,"eighty":26.125394,"marketCap":12415520},{"date":"2025-01-24","current":9.780279,"twenty":10.25185,"median":19.354401,"eighty":26.087984,"marketCap":13817600},{"date":"2025-01-31","current":8.55813,"twenty":9.931507,"median":18.990258,"eighty":25.926183,"marketCap":12088368},{"date":"2025-02-07","current":8.034161,"twenty":9.67709,"median":18.942456,"eighty":25.806345,"marketCap":11354816},{"date":"2025-02-14","current":7.429972,"twenty":9.170381,"median":18.736365,"eighty":25.661057,"marketCap":10499344},{"date":"2025-02-21","current":7.182682,"twenty":8.786233,"median":18.611629,"eighty":25.398607,"marketCap":10166096},{"date":"2025-02-28","current":6.088957,"twenty":8.49005,"median":18.298903,"eighty":25.263582,"marketCap":8617712},{"date":"2025-03-07","current":6.285152,"twenty":8.101774,"median":18.113266,"eighty":25.252549,"marketCap":8900160},{"date":"2025-03-14","current":5.596631,"twenty":7.768683,"median":17.68941,"eighty":25.185699,"marketCap":7924800},{"date":"2025-03-21","current":6.28575,"twenty":7.480228,"median":17.54621,"eighty":25.06182,"marketCap":8900160},{"date":"2025-03-28","current":6.3175,"twenty":7.319362,"median":17.202773,"eighty":24.992177,"marketCap":8940800},{"date":"2025-04-04","current":6.433722,"twenty":7.066391,"median":16.81288,"eighty":24.761928,"marketCap":9104010},{"date":"2025-04-11","current":7.43656,"twenty":6.901399,"median":16.523806,"eighty":24.668714,"marketCap":10546080},{"date":"2025-04-17","current":5.733501,"twenty":6.823071,"median":16.327956,"eighty":24.52062,"marketCap":8128000},{"date":"2025-04-22","current":5.658267,"twenty":6.492664,"median":16.072677,"eighty":24.474222,"marketCap":8026400}],"updateTime":1745422090166}}}